On this page
Quick Reference
Overview and Recommendations
Background
- •Bacterial meningitis, an acute purulent infection of the (CSF) and subarachnoid space, represents a critical failure of the (BBB) following bacterial translocation from the nasopharynx or direct inoculation.
- •Streptococcus pneumoniae is now the leading cause of community-acquired bacterial meningitis in adults (58%), followed by Group B Streptococcus (18%) and (14%), while remains a significant threat to the elderly, pregnant, and immunocompromised.
- •The pathophysiology is driven less by the bacterial load and more by the host's 'cytokine storm' (IL-1β, TNF-α), which induces vasogenic, cytotoxic, and interstitial edema, leading to elevated intracranial pressure (ICP) and potential brain herniation.
- •Epidemiological shifts have increased the median age of infection from 30 to 42 years in vaccinated populations, though children under age 5 still account for over one-third of global meningitis deaths.
- •Prognostic stakes are exceptionally high, with untreated mortality approaching 100% and treated mortality for pneumococcal strains remaining near 30% in adults; survivors face a 10-year epilepsy risk of 4.1%.
Evaluation
- •Suspect bacterial meningitis in any patient presenting with the rapid onset (24-48 hours) of fever, headache, and meningismus, though the classic triad including altered mental status is absent in nearly 50% of cases.
- •Perform a rapid neurological assessment using the (GCS) or the FOUR score; a GCS ≤ 8 indicates a need for immediate airway protection and suggests high ICP.
- •Examine for focal neurological deficits, cranial nerve palsies, and systemic signs such as purpura fulminans (suggestive of ) or parameningeal infections like otitis and mastoiditis.
- •Order a (CSF) analysis via lumbar puncture (LP) as the gold-standard diagnostic step, ideally performed within 1 hour of presentation.
- •Obtain a cranial CT prior to LP only if specific 'red flags' are present: GCS < 10, new-onset seizures, focal neurologic deficits, papilledema, or severe immunocompromise.
- •Analyze CSF for classic bacterial markers: neutrophilic pleocytosis (often >1,000 cells/mm³), low glucose (hypoglycorrhachia), and elevated protein.
- •Utilize rapid molecular testing, such as multiplex PCR panels (e.g., BioFire), to identify pathogens within hours, especially if the patient received antibiotics prior to the LP.
- •Consider novel biomarkers like CSF Heparin-Binding Protein (HBP > 5.2 ng/ml) or Lipocalin-2 (LCN-2 > 100.7 ng/mL) to differentiate bacterial from viral etiologies when leukocyte counts are equivocal.
- •Monitor systemic markers, specifically the blood urea nitrogen to albumin (BUN/ALB) ratio; a ratio > 5.13 is a robust predictor of unfavorable 3-month outcomes.
- •Evaluate for vascular complications using MRI with Diffusion-Weighted Imaging (DWI) if the patient has focal deficits, as ischemic stroke occurs in 16% of cases.
Management
- •Initiate empiric antimicrobial therapy and adjunctive steroids immediately; do not delay treatment for neuroimaging if the patient is clinically deteriorating.
- •Administer 10 mg IV (or 0.15 mg/kg in children) 15-20 minutes before or concurrently with the first dose of antibiotics to reduce the risk of hearing loss and mortality.
- •Start empiric antibiotics: 2 g IV every 12 hours plus 15-20 mg/kg IV every 8-12 hours to cover resistant pneumococci.
- •Add 2 g IV every 4 hours in patients > 50 years old, pregnant women, or the immunocompromised to cover .
- •Maintain intracranial pressure (ICP) < 20 mmHg using head-of-bed elevation, osmotherapy (mannitol or hypertonic saline), and, if necessary, external ventricular drainage.
- •Titrate vancomycin carefully in pediatric patients; an eGFR ≥ 169 mL/min/1.73 m² often leads to subtherapeutic troughs and requires higher dosing or more frequent monitoring.
- •Control seizures aggressively with IV benzodiazepines followed by levetiracetam or fosphenytoin, as status epilepticus carries a 15% in-hospital mortality rate.
- •De-escalate therapy once cultures and sensitivities are available; for confirmed S. pneumoniae, continue treatment for 10-14 days; for N. meningitidis, 7 days is typically sufficient.
- •Avoid adjunctive dexamethasone in patients with advanced HIV or in resource-poor settings where it has failed to show benefit and may increase mortality.
- •Refer all survivors for formal audiological testing and neurocognitive assessment within 3 months of discharge, as sequelae prevalence nearly doubles during this window.
- •Consider early for patients with profound hearing loss to bypass potential cochlear ossification.
- •Monitor for delayed cerebral thrombosis, which can occur 7-19 days after initial improvement, particularly in pneumococcal cases.
Board Review — High Yield
- •Classic Triad, Fever, neck stiffness, and altered mental status; only present in ~50% of adult cases.
- •Dexamethasone Timing, Must be given before or with the first dose of antibiotics to be effective in reducing neuroinflammation.
- •CSF Leukocytes, A count < 1,000 cells/mm³ is paradoxically associated with worse prognosis (overwhelmed immune response).
- •Listeria Coverage, Ampicillin must be added for those >50, pregnant, or immunocompromised; ceftriaxone does not cover Listeria.
- •Hearing Loss, The most common long-term sequela, affecting up to 34% of survivors; dexamethasone reduces this risk.
- •Waterhouse-Friderichsen Syndrome, Adrenal hemorrhage and insufficiency associated with meningococcemia.
- •Post-Meningitic Epilepsy, 10-year risk is ~4%, significantly higher than the general population.
- •Vaccine Shift, Conjugate vaccines have shifted the median age of infection from children to older adults (median age ~42).
Deep Dive — Evidence Details
Definition, Classification & Nomenclature
- ▸Mortality for infants <1 year remains high at 4.2% despite overall declining incidence [7].
- ▸Long-term sequelae affect 37.3% of survivors, primarily cognitive and auditory deficits [9].
Bacterial meningitis is an acute inflammatory syndrome of the caused by bacterial invasion [1]A1b[9]A1a. It is classified by acquisition (Community-acquired vs. Healthcare-associated), etiology (Pyogenic vs. Granulomatous/ ), and duration (Acute vs. Chronic >4 weeks) [2]C4[5]C4[6]A1a. While pediatric hospitalization rates fell 50% between 2010-2018, mortality for infants <1 remains high at 4.2% [7]B2c. Survivors face a 37.3% complication rate, including cognitive impairment (21.6%) and hearing loss (14.3%) [9]A1a. Post-meningitic epilepsy risk is 4.1% over 10 years [3]B3b. Aseptic meningitis refers to meningeal inflammation with negative routine cultures, often viral but sometimes partially treated bacterial cases. Pearl: Always distinguish between pyogenic and tuberculous meningitis early, as the latter requires specific scoring systems for diagnosis and carries a high (38%) association with HIV in adults [6]A1a[8]B2b.
| Classification Axis | Variants | Key Distinguishing Features |
|---|---|---|
| Acquisition | Community-acquired | Occurs in the absence of recent healthcare contact or neurosurgical intervention. |
| Healthcare-associated | Follows neurosurgical procedures, head trauma, or device placement (e.g., Ommaya reservoir) [2]C4[5]C4. | |
| Etiology | Pyogenic | Caused by common pathogens like S. pneumoniae or N. meningitidis. |
| Granulomatous | Specifically refers to Tuberculous meningitis (TBM) [6]A1a[8]B2b. | |
| Duration | Acute | Symptoms develop over hours to days. |
| Chronic | Symptoms persist for >4 weeks; often associated with M. tuberculosis. |
Pathophysiology & Mechanism
- ▸BBB disruption occurs via Vimentin-mediated translocation and ZO-1 downregulation [16, 17].
- ▸Host inflammatory response, not just bacterial load, drives neuronal damage and ICP elevation [10, 12].
Pathogens cross the (BBB) via adhesion to microvascular endothelial cells, often utilizing the Vimentin-NF-κB pathway and downregulating tight junction proteins like ZO-1 [16]D5[17]D5. Once in the subarachnoid space, a "cytokine storm" (IL-1β, TNF-α) triggers neutrophil infiltration and cerebral edema (vasogenic, cytotoxic, and interstitial) [20]D5. Genetic susceptibility is linked to the TLR4 rs4986790 polymorphism [15]A1a. Elevated intracranial pressure (ICP) risks brain herniation [14]A1a. Interestingly, the brain attempts repair via increased neural progenitor proliferation in the dentate gyrus (p=0.0075) [11]C4. Pearl: The severity of bacterial meningitis is driven less by the bacterial load itself and more by the host's dysregulated inflammatory response to bacterial cell wall components, which justifies the use of adjunctive to modulate this cascade [10]D5[12]D5.
Epidemiology, Etiology & Risk Factors
- ▸S. pneumoniae is the dominant adult pathogen, causing nearly 60% of US cases [26].
- ▸Active cancer and HIV are major independent risk factors for community-acquired infection [21, 31].
Global burden in 2023 reached 2.54 million cases and 259,000 deaths [27]B2c. In the US, incidence is 1.38 per 100,000, with the median age shifting from 30.3 to 41.9 years [26]B2c. is the leading cause (58% US, 37% Denmark), carrying up to 30% mortality [24]C4[26]B2c[45]B2b. Group B Streptococcus (GBS) follows (18.1%), while (3.4%) targets the elderly and immunocompromised [25]C4[26]B2c. Active cancer increases risk 2.71-3.52x [31]B2b. Environmental risks include household air pollution and low birthweight [27]B2c. Pearl: The median age of bacterial meningitis has shifted to the fifth decade of life in vaccinated populations, where Streptococcus pneumoniae now accounts for nearly 60% of cases and carries a 30% mortality rate [24]C4[26]B2c.
| Pathogen | U.S. Prevalence (2003-2007) [26]B2c | Denmark Prevalence (2015-2023) [45]B2b |
|---|---|---|
| S. pneumoniae | 58.0% | 37% |
| Group B Streptococcus | 18.1% | 7% (β-haemolytic) |
| N. meningitidis | 13.9% | 5% |
| H. influenzae | 6.7% | Not specified |
| L. monocytogenes | 3.4% | Not specified |
| S. aureus | Not specified | 8% |
| Unknown Aetiology | Not specified | 20% |
Clinical Presentation
- ▸Absence of the classic triad does NOT rule out meningitis; 2/3 features or low GCS require immediate action [33, 37].
- ▸Infants often lack meningismus, presenting instead with bulging fontanels and seizures [53].
The classic triad (fever, neck stiffness, altered mental status) is frequently incomplete [33]D5[50]D5. Fever is present in 98% of pediatric cases [53]B3b. A low ( ) score is a robust predictor of poor outcomes [24]C4[37]B2b. Focal deficits or cranial nerve palsies suggest vascular complications or high ICP [24]C4[47]C4. Infants <12 months often present atypically with bulging fontanels (34.1%) and convulsions (48.4%) [53]B3b. Postoperative cases may only show fever and vomiting [55]B3b. Delayed neurological decline (7-19 days post-onset) may indicate cerebral thrombosis [47]C4. Pearl: The absence of the classic triad (fever, neck stiffness, altered mental status) does not rule out bacterial meningitis; however, the presence of at least two of these features, or a low GCS score, should trigger immediate CSF analysis and empiric therapy [33]D5, [37]B2b.
| Variant | Key Features | Frequency/Context |
|---|---|---|
| Pneumococcal | High inflammatory markers, frequent altered mental status, high risk of neurological sequelae [46]A1b | Most common adult form (37%) [45]B2b |
| Listerial | More common in cancer patients (21% vs 5%); may present as rhombencephalitis or ventriculitis [25]C4, [31]B2b | 5-21% depending on host [31]B2b |
| Postoperative | Atypical presentation; fever and vomiting predominate; rare meningeal signs [55]B3b | Following neurosurgery [55]B3b |
| Staphylococcal | Often associated with bacteremia and lower CSF leukocyte counts; higher 30-day mortality (22%) [45]B2b | 8% of adult cases [45]B2b |
Diagnosis & Workup
- ▸CSF leukocytes <1,000 cells/mm³ paradoxically predict worse outcomes [24, 37].
- ▸Perform neuroimaging before LP only if GCS <10, focal signs, or papilledema are present [50].
Lumbar puncture (LP) is the gold standard and should occur within 1 hour [33]D5. CT/MRI is required pre-LP if GCS <10, new seizures, or focal deficits exist [50]D5. CSF findings typically show leukocytes >1,000 cells/mm³, low glucose (AUC 0.87-0.95), and high protein [24]C4[65]B2b. Novel biomarkers like CSF HBP (>5.2 ng/ml) and LCN-2 (>100.7 ng/mL) help differentiate bacterial from viral causes [67]B2b[68]B2b. Multiplex PCR (e.g., BioFire) provides rapid identification [73]C4. MRI with DWI is superior for detecting ischemic stroke (16% of cases) [59]A1a. Pearl: Do not delay antibiotics for neuroimaging or LP in a deteriorating patient; a CSF leukocyte count <1,000 cells/mm³ or the presence of gram-positive cocci on Gram stain are early indicators of a high-risk clinical course [37]B2b, [24]C4.
| Biomarker | Cut-off | Sensitivity | Specificity | AUC (95% CI) |
|---|---|---|---|---|
| HBP | 5.2 ng/ml | 97% | 96% | 0.98 (0.96-1.00) |
| HBP + CRP | 0.07 | 100% | 96% | 1.00 (0.99-1.00) |
| LCN-2 | 100.7 ng/mL | 83.3% | 60.0% | Not reported |
| Metabolites | N/A | N/A | N/A | 0.87-0.95 |
Severity, Staging & Risk Stratification
- ▸Dutch Meningitis Risk Score is the validated bedside tool for 1-hour prognosis [37].
- ▸Systemic failure (shock, AKI) is the primary mortality driver in the elderly [24, 52].
The Dutch Meningitis Risk Score (Age, HR, GCS, CN palsies, CSF WBC <1,000, Gram+ cocci) predicts unfavorable outcomes (C-index 0.84) [37]B2b. The FOUR Score is superior for GCS 3 patients [62]B2b. Seizures (17% of adults) increase mortality to 41% [32]B2b. Systemic complications (septic shock, AKI) drive 59% of deaths in patients ≥60 years, while younger patients more often die from neurological failure like herniation [24]C4[52]B3b. MDR infections triple 30-day mortality risk [78]B3b. Pearl: A CSF leukocyte count < 1,000 cells/mm³ is a paradoxical marker of high severity, reflecting an overwhelmed immune response and predicting a significantly higher risk of death [24]C4[37]B2b.
| Variable | Hazard Ratio (95% CI) | Significance |
|---|---|---|
| Age | 1.04 (1.01-1.08) | Per year increase |
| Neurological Complications | 2.31 (1.12-4.78) | e.g., stroke, herniation |
| MDR Infection | 3.15 (1.42-6.99) | Multidrug resistance |
| CSF Neutrophil % | 1.03 (1.01-1.05) | Higher percentage |
| Serum C-reactive Protein | 1.12 (1.03-1.22) | Systemic inflammation |
Acute Management
- ▸Target antibiotic + steroid administration within 60 minutes of arrival [84].
- ▸Maintain ICP <20 mmHg; consider EVD for monitoring and CSF diversion [82, 125].
Stabilize airway if GCS ≤ 8 [79]C4. Time to antibiotics is the critical survival determinant; only 22.2% receive them within the target 1 hour [84]B3b. Empiric Therapy: Initiate and (0.15 mg/kg) immediately [61]D5[84]B3b. Dexamethasone reduces severe disability if given with or before the first antibiotic dose [84]B3b. For elevated ICP, maintain <20 mmHg via EVD or osmotherapy [82]A1a[125]D5. Otogenic cases may require surgery within 48 hours if medical therapy fails [81]A1c. (100-200 mg BID) may promote neurorecovery in persistent disorders of consciousness [80]A1a. Pearl: Administer and within 1 hour of arrival; delays beyond this window are associated with increased neurologic sequelae, which affect nearly 25% of survivors at discharge [39]A1a[84]B3b.
Long-term & Definitive Management
- ▸Dexamethasone NNT is 18 to prevent one case of pediatric hearing loss [86].
- ▸Avoid adjunctive steroids in HIV-positive adults in resource-limited settings [21].
Tailor antibiotics to CSF culture. Neonatal courses of 10 days are often equivalent to 14 days [94]A1b. In infants <60 days, + is equivalent to [88]A1b. Dexamethasone (10 mg q6h for 4 days in adults) provides a 20-year survival benefit in high-income settings (22% vs 33% mortality) [1]A1b. In children, it reduces hearing loss (NNT = 18) [86]A1a. However, in HIV-prevalent, resource-poor settings (e.g., sub-Saharan Africa), dexamethasone fails to reduce mortality and may be omitted [21]A1b[87]A1a. Oral glycerol is controversial and potentially harmful in adults [89]A1b[92]A1b. Pearl: Adjunctive dexamethasone must be tailored to the environment; while it provides a 20-year survival benefit in high-resource settings, it increases mortality or provides no benefit in HIV-prevalent, resource-limited regions [1]A1b[21]A1b[92]A1b.
History and Evolution of Treatment
- ▸Ceftriaxone replaced cefuroxime due to faster CSF sterilization and lower hearing loss rates [97].
- ▸Steroids must be given BEFORE or WITH the first antibiotic dose to be effective [96].
Treatment evolved from / to third-generation cephalosporins in the 1980s. proved superior to , reducing hearing loss from 17% to 4% [97]A1b. The 2002 European Dexamethasone Study confirmed steroids reduce unfavorable outcomes (RR 0.59) and mortality (RR 0.48) in adults [96]A1b. Vaccination has revolutionized prevention: Hib is nearly eliminated in many regions [34]D5, and the PsA-TT vaccine achieved ≥93% seroconversion in the African Meningitis Belt [110]A1b. Pearl: Adjunctive dexamethasone must be administered prior to or with the first dose of to be effective; its benefit is most pronounced in pneumococcal meningitis in high-income settings, reducing mortality by approximately 50% (RR 0.48) [96]A1b.
| Agent | Comparison | Key Outcome | Reference |
|---|---|---|---|
| Ceftriaxone | vs. Cefuroxime | Lower hearing loss (4% vs 17%) | [97]A1b |
| Ceftriaxone | vs. Amp/Chlor | Greater CSF bactericidal activity | [101]A1b |
| Chloramphenicol | vs. Cephalosporins | Higher bacteriological failure rates | [102]A1b |
| Ceftriaxone (5d) | vs. Ceftriaxone (10d) | Equivalent safety and relapse rates | [103]A1b |
Disease-Modifying & Immunotherapy Program
- ▸Use TDM to individualize dosing for resistant organisms or complex abscesses [124].
- ▸Aggressive ICP management (<20 mmHg) is essential to reduce mortality [125].
Modern management integrates ICP monitoring, TCCD for hemodynamics, and therapeutic drug monitoring (TDM) [122]C4[124]C4. Maintain ICP <20 mmHg [125]D5. In ME-panel negative pediatric cases, off-label BCID2 testing can identify resistance genes (VIM, vanA/B), leading to treatment escalation in 56.5% of cases [128]B3b. Anaerobic infections (oral flora) require + for 6 weeks [124]C4. Future targets include the PNAG polysaccharide for GBS and E. coli K1 immunization [127]D5. Pearl: Maintain ICP <20 mmHg through aggressive intervention and utilize TDM to individualize therapy in complex or resistant infections to reduce the high mortality associated with neurologic deterioration [124]C4[125]D5.
Neurorehabilitation & Supportive Care
- ▸Neurological sequelae often worsen or manifest after discharge; 3-month follow-up is mandatory [39].
- ▸Cochlear implants are effective but must be performed before post-meningitic ossification [134].
Sequelae prevalence rises from 24.8% at discharge to 41.5% at 3 months [39]A1a. Hearing loss (15-18%) requires early audiometric testing; is the standard for profound loss but is complicated by cochlear ossification [134]A1a[130]B2b. Depressive symptoms affect >30% [130]B2b. Watch for late-onset causing "man-in-the-barrel" syndrome (proximal arm weakness) [48]C4. Post-infectious requires IVIG [71]C4. Pearl: Because the prevalence of neurological sequelae nearly doubles between hospital discharge (24.8%) and the 3-month follow-up (41.5%), a formal outpatient neuro-rehabilitative assessment is mandatory for all survivors [39]A1a.
Complications
- ▸Ischemic stroke occurs in 16% of cases and more than doubles mortality risk [59].
- ▸Seizures in the first 24 hours are a major risk factor for status epilepticus and death [32, 23].
Neurologic complications affect 39-50% of adults [24]C4. Seizures (17%) and Ischemic Stroke (16%) are common; stroke OR for mortality is 2.38 [32]B2b[59]A1a. Infratentorial empyema is rare but requires neurosurgery [60]C4. Systemic failure (septic shock, AKI) is the primary mortality driver in the elderly [24]C4[52]B3b. Sensorineural hearing loss affects 24-34% of survivors [135]A1a[40]A1a. Cognitive dysfunction (21% in pneumococcal cases) involves executive and memory deficits [46]A1b[75]B3b. Pearl: Systemic complications, rather than primary neurologic failure, are the leading cause of death in elderly patients with bacterial meningitis, necessitating aggressive management of shock and organ dysfunction alongside antimicrobial therapy [24]C4.
| Complication | Frequency | Prevention/Monitoring | Management |
|---|---|---|---|
| Seizures | 17% (Adults) [32]B2b | EEG monitoring in comatose patients [32]B2b | Anticonvulsants; duration of therapy is individualized [136]A1a |
| Ischemic Stroke | 16% [59]A1a | Monitoring for focal deficits [59]A1a | Supportive care; mortality OR is 2.38 if stroke occurs [59]A1a |
| Hearing Loss | ~24-30% [135]A1a, [40]A1a | Adjunctive [135]A1a | Formal audiological testing at discharge and follow-up [40]A1a |
| Cerebral Edema | Variable [66]D5 | Head-of-bed elevation; | Invasive ICP monitoring (no proven mortality benefit) [52]B3b |
Prognosis & Natural History
- ▸BUN/ALB ratio >5.13 is a powerful systemic biomarker for poor 3-month prognosis [69].
- ▸Pneumococcal etiology carries double the mortality rate of other common bacterial causes [24].
US case fatality is 14.3-15.7%, but pneumococcal meningitis mortality reaches 30% [24]C4[26]B2c. In Malawi, mortality is >50% [21]A1b. Predictors of poor outcome include GCS <10, CSF WBC <1,000, and a BUN/ALB ratio >5.13 [37]B2b[69]B3b. Survivors face high rates of epilepsy and cognitive impairment [36]D5[46]A1b. Dexamethasone's survival benefit persists for 20 years in high-income settings [1]A1b. Pearl: The prognosis of bacterial meningitis is often fixed within the first hour of presentation; a CSF leukocyte count < 1,000 cells/mm³ or a low Glasgow Coma Scale score are high-intensity red flags for an unfavorable 90-day outcome [24]C4[37]B2b.
| Factor | Clinical Significance | Evidence |
|---|---|---|
| Age | Independent predictor of death after the acute phase | [1]A1b[45]B2b |
| Pathogen | S. aureus and β-haemolytic streptococci associated with higher mortality | [45]B2b |
| Stroke | Occurs in 16% of cases; associated with higher mortality (OR 2.38) | [59]A1a |
| Seizures | Early seizures increase the risk of long-term epilepsy | [36]D5 |
Special Populations & Pregnancy
- ▸High eGFR in children leads to vancomycin treatment failure due to rapid clearance [142].
- ▸CSVT is a frequent pediatric complication, especially with concurrent mastoiditis [30].
In children, CSVT occurs in 31% of intracranial infections; risk factors include mastoiditis (aOR 12.2) and dehydration [30]B3b. Pediatric patients with high eGFR (≥169.21 mL/min) often have subtherapeutic levels, predicting poor outcomes [142]B3b. Pregnancy is a major risk for Listeria [25]C4. In the elderly, systemic failure causes 59% of deaths [24]C4. The PECARN rule helps identify low-risk febrile infants (NPV 99.4%) [141]B2b. Pearl: In pediatric patients, an eGFR ≥169.21 mL/min/1.73 m² is a critical threshold for vancomycin under-dosing and predicts poor clinical outcomes [142]B3b.
| Risk Factor | Adjusted Odds Ratio (aOR) | 95% Confidence Interval |
|---|---|---|
| Mastoiditis | 12.2 | 3.1-48.5 |
| Extra-axial focal suppurative infection | 10.2 | 1.7-61.6 |
| Cerebritis | 4.6 | 1.5-14.5 |
| Dehydration | 3.9 | 1.0-15.1 |
Prevention, Screening & Surveillance
- ▸PCV13/20 and Hib vaccines are the primary tools for reducing global meningitis burden [22, 146].
- ▸Antimicrobial resistance in S. pneumoniae is rising, with 27.4% penicillin resistance globally [41].
Vaccination has reduced US rates by 55% [26]B2c. Hib vaccination can nearly eliminate disease [22]A1a. covers 81.3% of pediatric serotypes, but non-vaccine serotypes are emerging, necessitating [53]B3b[146]B2b. Universal GBS screening in pregnancy has shifted neonatal epidemiology [26]B2c. Global AMR for benzylpenicillin in S. pneumoniae is 27.4% [41]A1a. Pearl: Vaccination has shifted the burden of bacterial meningitis toward older adults, with the median age of patients in the United States increasing from 30.3 to 41.9 years as pediatric vaccine coverage expanded [26]B2c.
| Pathogen | Global Impact (2023) | Prevention Status |
|---|---|---|
| S. pneumoniae | Leading cause of death | Preventable via PCV13/PCV20 |
| N. meningitidis | Major cause of epidemics | Preventable via conjugate vaccines |
| H. influenzae | 8.13 million illnesses (2000) | Near elimination in high-vaccination areas |
| Group B streptococcus | Significant neonatal burden | Targeted via maternal screening |
References
- [1]
Fritz D, Brouwer MC, van de Beek D. “Dexamethasone and long-term survival in bacterial meningitis.” Neurology (2012). PMID: 23152589 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Prognosis & Natural History - [2]
Bergman J, Burman J, Gilthorpe JD et al.. “Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.” Neurology (2018). PMID: 30305449 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Prognosis & Natural History - [3]
Zelano J, Westman G. “Epilepsy after brain infection in adults: A register-based population-wide study.” Neurology (2020). PMID: 32989110 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification - [4]
Moshe-Lilie O, Visser A, Chahin N et al.. “Nusinersen in adult patients with spinal muscular atrophy: Observations from a single center.” Neurology (2020). PMID: 32665408 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Complications - [5]
Bergman J, Burman J, Bergenheim T et al.. “Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.” Journal of neurology (2020). PMID: 32901316 ↗
L4RCTCited in: Definition, Classification & Nomenclature - [6]
Pormohammad A, Nasiri MJ, Riahi SM et al.. “Human immunodeficiency virus in patients with tuberculous meningitis: systematic review and meta-analysis.” Tropical medicine & international health : TM & IH (2018). PMID: 29660820 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [7]
Kim BG, Jang MS, Kim J. “Epidemiology of Pediatric Meningitis in South Korea From 2010 to 2018: A Population-based Retrospective Cohort Study.” The Pediatric infectious disease journal (2021). PMID: 33990524 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [8]
Solomons RS, Visser DH, Marais BJ et al.. “Diagnostic accuracy of a uniform research case definition for TBM in children: a prospective study.” The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease (2016). PMID: 27287642 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [9]
Araújo RD, Diniz LMO, Teixeira DC et al.. “Long-Term Outcomes Following Bacterial Meningitis in Childhood: A Systematic Review and Meta-Analysis.” Journal of paediatrics and child health (2026). PMID: 42267426 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [10]
Weisfelt M, de Gans J, van der Poll T et al.. “Pneumococcal meningitis in adults: new approaches to management and prevention.” The Lancet. Neurology (2006). PMID: 16545750 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [11]
Gerber J, Tauber SC, Armbrecht I et al.. “Increased neuronal proliferation in human bacterial meningitis.” Neurology (2009). PMID: 19786694 ↗
L4OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [12]
McGill F, Heyderman RS, Panagiotou S et al.. “Acute bacterial meningitis in adults.” Lancet (London, England) (2016). PMID: 27265346 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications, Prognosis & Natural History - [13]
Roxas PB, Cruz J, Horelka NR et al.. “Typhus group Rickettsia community-acquired bacterial central nervous system infections: We must think outside the box!” Journal of the neurological sciences (2024). PMID: 39447222 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [14]
Procházka V, Skalický P, Banovčanová L et al.. “Rethinking lumbar puncture safety: pathophysiology, diagnostic uncertainty, and research gaps in herniation risk.” Acta neurologica Belgica (2025). PMID: 40804214 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [15]
Sekar PKC, Veerabathiran R. “Assessing the Impact of TLR4 rs4986790 Polymorphism on Bacterial Meningitis Risk: A Systematic Review and Meta-Analysis.” Annals of Indian Academy of Neurology (2024). PMID: 39576034 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [16]
Li Z, Chen M, Du Y et al.. “Integrated transcriptomic and proteomic analysis reveals inflammatory activation and blood-brain barrier disruption during meningitis-associated extraintestinal pathogenic Escherichia coli infection.” Virulence (2026). PMID: 42115138 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [17]
Zhou B, Meng X, Yu Z et al.. “Vimentin-NF-κB signaling contributing to IbeA-mediated adhesion, invasion, and biofilm formation during Escherichia coli K1 traversal of the blood-brain barrier.” Frontiers in immunology (2026). PMID: 42079636 ↗
L5OTHERCited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [18]
Kozák M, Mechtler L, Ralyea C et al.. “Headache Attributed to Infection: A Clinical and Pathophysiological Overview.” Current pain and headache reports (2026). PMID: 41949738 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Acute Management: Neurologic Emergencies & Attack Abortion - [19]
Scott TL, Quezado M, Williamson PR. “Update on the diagnosis, pathophysiology and treatment strategies in non-HIV-associated cryptococcal meningoencephalitis.” Expert review of anti-infective therapy (2026). PMID: 41661810 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization), Acute Management: Neurologic Emergencies & Attack Abortion - [20]
Shi Y, Liang T, Shi C et al.. “Molecular mechanisms of streptococcal disruption of the blood-brain barrier and their pathogenic role in bacterial meningitis.” Frontiers in immunology (2026). PMID: 41573555 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism (Neuroanatomic Localization) - [21]
Scarborough M, Gordon SB, Whitty CJ et al.. “Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa.” The New England journal of medicine (2007). PMID: 18077809 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Long-term & Definitive Management (Evidence Ladder), History and Evolution of Treatment, Complications, Prognosis & Natural History - [22]
Watt JP, Wolfson LJ, O'Brien KL et al.. “Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates.” Lancet (London, England) (2009). PMID: 19748399 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications, Prevention, Screening & Surveillance - [23]
Sadarangani M, Seaton C, Scott JA et al.. “Incidence and outcome of convulsive status epilepticus in Kenyan children: a cohort study.” The Lancet. Neurology (2008). PMID: 18248771 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [24]
Weisfelt M, van de Beek D, Spanjaard L et al.. “Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series.” The Lancet. Neurology (2006). PMID: 16426988 ↗
L4CASE_REPORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History, Special Populations & Pregnancy - [25]
Zhao CW, Dai S, Wu Q. “Pearls & Oy-sters: Diagnosis and Subtyping of Listeria Ventriculitis in an Immunocompetent Host.” Neurology (2022). PMID: 35508397 ↗
L4CASE_REPORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Special Populations & Pregnancy - [26]
Thigpen MC, Whitney CG, Messonnier NE et al.. “Bacterial meningitis in the United States, 1998-2007.” The New England journal of medicine (2011). PMID: 21612470 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [27]
. “Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.” The Lancet. Neurology (2026). PMID: 41911930 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [28]
van Samkar A, Brouwer MC, van der Ende A et al.. “Zoonotic bacterial meningitis in human adults.” Neurology (2016). PMID: 27534710 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [29]
Kasanmoentalib ES, Brouwer MC, van der Ende A et al.. “Hydrocephalus in adults with community-acquired bacterial meningitis.” Neurology (2010). PMID: 20820003 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [30]
Mehta N, Sheth N, Halverson M et al.. “Cerebral Sinovenous Thrombosis in Children With Acute Bacterial Intracranial Infection.” Neurology (2025). PMID: 41021871 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [31]
Costerus JM, Brouwer MC, van der Ende A et al.. “Community-acquired bacterial meningitis in adults with cancer or a history of cancer.” Neurology (2016). PMID: 26802096 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, History and Evolution of Treatment - [32]
Zoons E, Weisfelt M, de Gans J et al.. “Seizures in adults with bacterial meningitis.” Neurology (2008). PMID: 18305232 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Complications - [33]
van de Beek D, Brouwer MC, Koedel U et al.. “Community-acquired bacterial meningitis.” Lancet (London, England) (2021). PMID: 34303412 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prevention, Screening & Surveillance - [34]
McIntyre PB, O'Brien KL, Greenwood B et al.. “Effect of vaccines on bacterial meningitis worldwide.” Lancet (London, England) (2012). PMID: 23141619 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History, Prevention, Screening & Surveillance - [35]
Chin RF, Neville BG, Peckham C et al.. “Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study.” Lancet (London, England) (2006). PMID: 16844492 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [36]
Murthy JM, Prabhakar S. “Bacterial meningitis and epilepsy.” Epilepsia (2008). PMID: 18754955 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History - [37]
Weisfelt M, van de Beek D, Spanjaard L et al.. “A risk score for unfavorable outcome in adults with bacterial meningitis.” Annals of neurology (2008). PMID: 17823938 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History - [38]
Dionisopoulos Z, Sabhaney V, D'Arienzo D et al.. “Prevalence of Invasive Bacterial Infections Among Febrile Infants Aged 60 to 90 Days: A Systematic Review and Meta-Analysis.” JAMA pediatrics (2026). PMID: 42189531 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [39]
Alviz LF, Kim CY, Monette LE et al.. “Detection of sequelae from acute meningitis during clinical review by a healthcare provider: a systematic review and meta-analysis.” BMC medicine (2026). PMID: 41761295 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management: Neurologic Emergencies & Attack Abortion, Neurorehabilitation, Symptomatic & Supportive Care, Complications, Special Populations & Pregnancy - [40]
Alviz LF, Kim CY, Benevides-Tadinac AC et al.. “Detection of hearing loss by formal audiological testing after acute infectious meningitis: a global systematic review and meta-analysis.” BMC medicine (2026). PMID: 41761238 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications, Special Populations & Pregnancy - [41]
Lazarus G, Caddey B, Dean A et al.. “Antimicrobial resistance in bacterial meningitis caused by Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae (2010-24): a systematic review and meta-analysis.” The Lancet. Microbe (2026). PMID: 41616789 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [42]
Onohuean H, Choonara YE. “Epidemiological distribution of bacterial meningitis infections in South Africa: a systematic review and meta-analysis.” BMC infectious diseases (2025). PMID: 41073968 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [43]
Park AY, Kim HW. “Validation of Clinical Practice Guidelines for Febrile Young Infants in a Changing Epidemiological Context.” Pediatrics international : official journal of the Japan Pediatric Society (2026). PMID: 42047286 ↗
L2GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification - [44]
Bloch J, El Rhali L, Vissing N et al.. “The Spectrum of CNS Infections in Children and Adolescents in Denmark 2017-2023: A Multicenter Population-based Cohort Study.” The Pediatric infectious disease journal (2026). PMID: 41941117 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications, Special Populations & Pregnancy - [45]
Nielsen H, Storgaard M, Larsen L et al.. “Community-acquired bacterial meningitis in adults in Denmark (2015-2023): a prospective, nationwide, population-based cohort study.” The Lancet regional health. Europe (2026). PMID: 41767888 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prognosis & Natural History - [46]
Weisfelt M, Hoogman M, van de Beek D et al.. “Dexamethasone and long-term outcome in adults with bacterial meningitis.” Annals of neurology (2006). PMID: 16958121 ↗
L1RCTCited in: Clinical Presentation, History and Evolution of Treatment, Complications, Prognosis & Natural History - [47]
Schut ES, Brouwer MC, de Gans J et al.. “Delayed cerebral thrombosis after initial good recovery from pneumococcal meningitis.” Neurology (2009). PMID: 19890068 ↗
L4CASE_REPORTCited in: Clinical Presentation, Complications, Prognosis & Natural History - [48]
Karschnia P, Kaulen L, Thon N et al.. “Clinical Reasoning: A 64-Year-Old Man With History of Meningitis Presenting With Proximal Weakness of the Arms.” Neurology (2021). PMID: 34799459 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Neurorehabilitation, Symptomatic & Supportive Care - [49]
Pavuluri H, Kv V, Thomas B et al.. “Clinical Reasoning: A Teenager With Chronic Meningitis-Does Occam's Razor Apply?” Neurology (2023). PMID: 36746637 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [50]
Brouwer MC, Thwaites GE, Tunkel AR et al.. “Dilemmas in the diagnosis of acute community-acquired bacterial meningitis.” Lancet (London, England) (2012). PMID: 23141617 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Complications - [51]
Ray STJ, Fuller CE, Boubour A et al.. “The aetiologies, mortality, and disability of non-traumatic coma in African children: a systematic review and meta-analysis.” The Lancet. Global health (2025). PMID: 40280144 ↗
L1SR_OBSCited in: Clinical Presentation, Severity, Staging & Risk Stratification - [52]
Poirier C, Terzi N, Roesch N et al.. “Outcomes, prognostic factors, and the role of intracranial pressure monitoring in severe community-acquired bacterial meningitis: a multicenter retrospective cohort study.” The Lancet regional health. Europe (2026). PMID: 42436935 ↗
L3COHORTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History - [53]
Truong HC, Phan TV, Nguyen HT et al.. “Clinical features and antibiotic resistance in pediatric pneumococcal meningitis in Southern Vietnam, 2012-2023: A multicenter retrospective study.” Journal of infection and public health (2025). PMID: 40318609 ↗
L3COHORTCited in: Clinical Presentation, Prevention, Screening & Surveillance - [54]
Price M, Farthing S, Wong SH et al.. “Stroke Complicating Pediatric Bacterial Meningitis: A Retrospective Case-Controlled Cohort Analysis.” Pediatric neurology (2026). PMID: 42161222 ↗
L3CASE_CONTROLCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prevention, Screening & Surveillance - [55]
Han S, Fang Q, Zhou Z et al.. “Clinical features and risk factors for outcomes of postoperative bacterial meningitis in pediatric neurosurgery: a retrospective study from 2013 to 2023.” Frontiers in pediatrics (2026). PMID: 42221006 ↗
L3COHORTCited in: Clinical Presentation - [56]
Nabiuni M, Zarghami F. “First reported mortality from XDR Acinetobacter Baumannii Meningitis following posterior lumbar interbody fusion in Iran: a case report.” BMC infectious diseases (2026). PMID: 42374209 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [57]
Nguyen TH, Tran TH, Thwaites G et al.. “Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis.” The New England journal of medicine (2007). PMID: 18077808 ↗
L1RCTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment, Prognosis & Natural History - [58]
Schmidt C, Plate A, Angele B et al.. “A prospective study on the role of CXCL13 in Lyme neuroborreliosis.” Neurology (2011). PMID: 21422457 ↗
L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [59]
Beuker C, Werring N, Bonberg N et al.. “Stroke in Patients with Bacterial Meningitis: A Cohort Study and Meta-Analysis.” Annals of neurology (2023). PMID: 36806294 ↗
L1SR_OBSCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History - [60]
van de Beek D, Campeau NG, Wijdicks EF. “The clinical challenge of recognizing infratentorial empyema.” Neurology (2007). PMID: 17664407 ↗
L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications, Prognosis & Natural History - [61]
Scarborough M, Thwaites GE. “The diagnosis and management of acute bacterial meningitis in resource-poor settings.” The Lancet. Neurology (2008). PMID: 18565457 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Acute Management: Neurologic Emergencies & Attack Abortion, Prognosis & Natural History - [62]
van Ettekoven CN, Brouwer MC, Bijlsma MW et al.. “The FOUR score as predictor of outcome in adults with bacterial meningitis.” Neurology (2019). PMID: 31053662 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Complications - [63]
Moradiya Y, Murthy SB, Newman-Toker DE et al.. “Intraventricular thrombolysis in intracerebral hemorrhage requiring ventriculostomy: a decade-long real-world experience.” Stroke (2014). PMID: 25061080 ↗
L3OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, Acute Management: Neurologic Emergencies & Attack Abortion, Neurorehabilitation, Symptomatic & Supportive Care, Complications, Prognosis & Natural History - [64]
Höhne C, Wenzel M, Angele B et al.. “High mobility group box 1 prolongs inflammation and worsens disease in pneumococcal meningitis.” Brain : a journal of neurology (2013). PMID: 23518713 ↗
L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Prognosis & Natural History - [65]
Staal SL, Olie SE, van Weeghel M et al.. “Cerebrospinal Fluid Metabolome in Central Nervous System Infections: A Study of Diagnostic Accuracy.” Annals of neurology (2025). PMID: 40525505 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [66]
Pavan C, L R Xavier A, Ramos M et al.. “DNase Treatment Prevents Cerebrospinal Fluid Block in Early Experimental Pneumococcal Meningitis.” Annals of neurology (2021). PMID: 34397111 ↗
L5OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Complications - [67]
Olie SE, Staal SL, da Cruz Campos AC et al.. “Heparin-Binding Protein in Cerebrospinal Fluid as a Biomarker for Bacterial Meningitis: A Study of Diagnostic Accuracy.” Annals of neurology (2025). PMID: 39868663 ↗
L2OTHERCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [68]
Deniz M, Seyman D, Aykal G. “Cerebrospinal fluid lipocalin-2 and bactericidal/permeability-increasing protein in acute bacterial versus viral meningitis: a prospective study.” Infection (2026). PMID: 42234339 ↗
L2COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [69]
Liang A, Zhang Y, Li X et al.. “Association of the blood urea nitrogen to serum albumin ratio on prognosis in patients with bacterial meningitis: a retrospective cohort study.” Frontiers in cellular and infection microbiology (2026). PMID: 41929452 ↗
L3COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History - [70]
Zhang F, Yu Z, Pan J et al.. “Risk factors for acute neurological complications in neonatal bacterial meningitis: a retrospective cohort study.” Jornal de pediatria (2026). PMID: 41864622 ↗
L3COHORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [71]
Liu A, Liu Y, Shi L et al.. “Guillain-Barré syndrome following Escherichia coli meningitis after cupping therapy: a case report.” Frontiers in immunology (2026). PMID: 42254014 ↗
L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), Neurorehabilitation, Symptomatic & Supportive Care - [72]
Huang L, Xi Y, Yu M et al.. “Post-endoscopic neurosurgical Candida albicans meningoencephalitis diagnosed by targeted next-generation sequencing: a case report.” Frontiers in medicine (2026). PMID: 42180747 ↗
L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG), History and Evolution of Treatment - [73]
Kozák M, Majoros L, Bodnár F et al.. “When the meningitis-encephalitis panel is negative: off-label joint infection PCR detects CTX-M ESBL-producing Proteus mirabilis in adult meningoencephalitis.” BMC infectious diseases (2026). PMID: 42082938 ↗
L4CASE_REPORTCited in: Diagnosis & Workup (Neuroimaging, EEG, LP, NCS/EMG) - [74]
Koelman DLH, Brouwer MC, van de Beek D. “Targeting the complement system in bacterial meningitis.” Brain : a journal of neurology (2019). PMID: 31373605 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History - [75]
Schmidt H, Heimann B, Djukic M et al.. “Neuropsychological sequelae of bacterial and viral meningitis.” Brain : a journal of neurology (2005). PMID: 16364957 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification, Complications, Prognosis & Natural History - [76]
Kelani H, Ibrahim N, Naeem A et al.. “Efficacy and safety of intraventricular nimodipine in patients with aneurysmal subarachnoid hemorrhage compared to oral nimodipine: a systematic review and meta-analysis.” Neurosurgical review (2025). PMID: 40383744 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification - [77]
Tang CM, Li HC, Su LH et al.. “Pneumococcal meningitis in children and adults before and after implementation of PCV13 into national pediatric immunization program: A cohort study in Taiwan.” Journal of infection and public health (2026). PMID: 42202671 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification, Complications, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [78]
Zhou J, Xing J, Cheng X et al.. “Development and validation of a predictive model for 30-day mortality in adult bacterial meningitis: a retrospective cohort study.” Frontiers in medicine (2025). PMID: 41357526 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification - [79]
Heide SK, Gnanaprakasam R, Bornovski Y et al.. “Clinical Reasoning: An Older Woman With Headaches and Lethargy After a Fall.” Neurology (2023). PMID: 37604660 ↗
L4CASE_REPORTCited in: Acute Management: Neurologic Emergencies & Attack Abortion - [80]
Loggini A, Saleh Velez FG, Hornik J et al.. “Amantadine use during acute hospitalization for neurological recovery after stroke: a systematic review.” Topics in stroke rehabilitation (2026). PMID: 42086496 ↗
L1SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion, Complications, Prognosis & Natural History - [81]
Rubini A, Ronzani G, D'Alessandro E et al.. “Management of Otogenic Meningitis: A Proposal for Practical Guidelines from a Multicenter Experience with a Systematic Review.” Journal of clinical medicine (2024). PMID: 39336995 ↗
L1SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion - [82]
El-Hajj VG, Pettersson I, Gharios M et al.. “Detection and Management of Elevated Intracranial Pressure in the Treatment of Acute Community-Acquired Bacterial Meningitis: A Systematic Review.” Neurocritical care (2024). PMID: 38356077 ↗
L1SR_OBSCited in: Acute Management: Neurologic Emergencies & Attack Abortion - [83]
Alviz LF, Hasbun R, Thakur KT. “Global bacterial meningitis guidelines: from policy to action.” Current opinion in infectious diseases (2026). PMID: 42019482 ↗
L1REVIEW_NARRATIVECited in: Acute Management: Neurologic Emergencies & Attack Abortion - [84]
Baron F, Houard M, Degrendel M et al.. “Initial management and outcome of community-acquired bacterial meningitis in two French ICUs over a period of fifteen years.” BMC infectious diseases (2025). PMID: 41291460 ↗
L3OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion - [85]
Nagaraj G, Govindan V, Kumar CPG et al.. “Molecular detection and serotyping of acute bacterial meningitis pathogens in Indian children.” European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2025). PMID: 40580274 ↗
L3OTHERCited in: Acute Management: Neurologic Emergencies & Attack Abortion - [86]
Tian C, Jin S, Zhao Z et al.. “Association of Corticosteroid Treatment With Outcomes in Pediatric Patients With Bacterial Meningitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Clinical therapeutics (2022). PMID: 35272859 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [87]
Vardakas KZ, Matthaiou DK, Falagas ME. “Adjunctive dexamethasone therapy for bacterial meningitis in adults: a meta-analysis of randomized controlled trials.” European journal of neurology (2009). PMID: 19475753 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [88]
Molyneux EM, Dube Q, Banda FM et al.. “The Treatment of Possible Severe Infection in Infants: An Open Randomized Safety Trial of Parenteral Benzylpenicillin and Gentamicin Versus Ceftriaxone in Infants <60 days of Age in Malawi.” The Pediatric infectious disease journal (2017). PMID: 28263245 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [89]
Molyneux EM, Kawaza K, Phiri A et al.. “Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children.” The Pediatric infectious disease journal (2014). PMID: 24136368 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [90]
Gwer SA, Idro RI, Fegan G et al.. “Fosphenytoin for seizure prevention in childhood coma in Africa: a randomized clinical trial.” Journal of critical care (2013). PMID: 24135012 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [91]
Mourvillier B, Tubach F, van de Beek D et al.. “Induced hypothermia in severe bacterial meningitis: a randomized clinical trial.” JAMA (2013). PMID: 24105303 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [92]
Ajdukiewicz KM, Cartwright KE, Scarborough M et al.. “Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial.” The Lancet. Infectious diseases (2011). PMID: 21334262 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [93]
Peltola H, Roine I, Fernández J et al.. “Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2007). PMID: 17968821 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [94]
Mathur NB, Kharod P, Kumar S. “Evaluation of duration of antibiotic therapy in neonatal bacterial meningitis: a randomized controlled trial.” Journal of tropical pediatrics (2015). PMID: 25681965 ↗
L1RCTCited in: Long-term & Definitive Management (Evidence Ladder) - [95]
Thampy A, Alexander H, John JM et al.. “Early vs. delayed empiric antimicrobial treatment for suspected acute meningitis - a systematic review and meta-analysis.” BMC infectious diseases (2026). PMID: 41688940 ↗
L1SR_OBSCited in: Long-term & Definitive Management (Evidence Ladder), Prognosis & Natural History - [96]
de Gans J, van de Beek D. “Dexamethasone in adults with bacterial meningitis.” The New England journal of medicine (2002). PMID: 12432041 ↗
L1RCTCited in: History and Evolution of Treatment - [97]
Schaad UB, Suter S, Gianella-Borradori A et al.. “A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children.” The New England journal of medicine (1990). PMID: 2403654 ↗
L1RCTCited in: History and Evolution of Treatment - [98]
Odio CM, Faingezicht I, Paris M et al.. “The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis.” The New England journal of medicine (1991). PMID: 2027357 ↗
L1RCTCited in: History and Evolution of Treatment - [99]
Schaad UB, Lips U, Gnehm HE et al.. “Dexamethasone therapy for bacterial meningitis in children. Swiss Meningitis Study Group.” Lancet (London, England) (1993). PMID: 8102428 ↗
L1RCTCited in: History and Evolution of Treatment - [100]
Molyneux EM, Walsh AL, Forsyth H et al.. “Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial.” Lancet (London, England) (2002). PMID: 12133656 ↗
L1RCTCited in: History and Evolution of Treatment - [101]
del Rio MA, Chrane D, Shelton S et al.. “Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children.” Lancet (London, England) (1983). PMID: 6134039 ↗
L1RCTCited in: History and Evolution of Treatment - [102]
Peltola H, Anttila M, Renkonen OV. “Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Finnish Study Group.” Lancet (London, England) (1989). PMID: 2566824 ↗
L1RCTCited in: History and Evolution of Treatment - [103]
Molyneux E, Nizami SQ, Saha S et al.. “5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study.” Lancet (London, England) (2011). PMID: 21620467 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Prognosis & Natural History - [104]
Pécoul B, Varaine F, Keita M et al.. “Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis.” Lancet (London, England) (1991). PMID: 1681224 ↗
L1RCTCited in: History and Evolution of Treatment - [105]
Vesikari T, Esposito S, Prymula R et al.. “Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.” Lancet (London, England) (2013). PMID: 23324563 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis & Natural History - [106]
Shann F, Barker J, Poore P. “Chloramphenicol alone versus chloramphenicol plus penicillin for bacterial meningitis in children.” Lancet (London, England) (1985). PMID: 2863674 ↗
L1RCTCited in: History and Evolution of Treatment - [107]
Cascino GD, Luckstein RR, Sharbrough FW et al.. “Facial asymmetry, hippocampal pathology, and remote symptomatic seizures: a temporal lobe epileptic syndrome.” Neurology (1993). PMID: 8469330 ↗
L4OTHERCited in: History and Evolution of Treatment - [108]
Kilpi T, Anttila M, Kallio MJ et al.. “Severity of childhood bacterial meningitis and duration of illness before diagnosis.” Lancet (London, England) (1991). PMID: 1678083 ↗
L2OTHERCited in: History and Evolution of Treatment - [109]
Thwaites GE, Chau TT, Stepniewska K et al.. “Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features.” Lancet (London, England) (2002). PMID: 12414204 ↗
L3OTHERCited in: History and Evolution of Treatment - [110]
Hodgson A, Haidara FC, Sow SO et al.. “Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.” Vaccine (2025). PMID: 40966979 ↗
L1RCTCited in: History and Evolution of Treatment - [111]
Koedel U, Winkler F, Angele B et al.. “Role of Caspase-1 in experimental pneumococcal meningitis: Evidence from pharmacologic Caspase inhibition and Caspase-1-deficient mice.” Annals of neurology (2002). PMID: 11891827 ↗
L5OTHERCited in: History and Evolution of Treatment - [112]
Pyrgakis P, Papargyriou GE, Oostra A et al.. “Ecchordosis physaliphora of the clivus: a case series and narrative review of the literature.” Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale (2025). PMID: 40985092 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [113]
Benhalima I, Jacquemont L, Milière L et al.. “Meningitis due to Gemella sp. in a patient with severe ENT conditions: case report and review of the literature.” Annals of clinical microbiology and antimicrobials (2024). PMID: 39696290 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [114]
Tengsupakul S, Mulekar M, Bista BR et al.. “Clinical utility of a cerebrospinal fluid multiplex PCR meningitis/encephalitis panel in children: a retrospective review of positive results.” BMC infectious diseases (2026). PMID: 41787310 ↗
L3REVIEW_NARRATIVECited in: History and Evolution of Treatment - [115]
Ozisik L. “The New Era of Pneumococcal Vaccination in Adults: What Is Next?” Vaccines (2025). PMID: 40432110 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [116]
Maeda A, Hayashi K, Izumi R et al.. “Lumbar-peritoneal shunt-associated meningitis and peritoneal abscess due to Corynebacterium striatum: A case report and literature review.” Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (2025). PMID: 41391636 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [117]
Anand K, Selvam V, Renuka MK. “Navigating the complexities of severe Cushing's syndrome in the ICU: a case report.” Frontiers in medicine (2026). PMID: 42200054 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [118]
Liao L, Lau T, Meng J et al.. “Congenital HSV-2 infection with atypical skin lesions, chorioretinitis, and neurodevelopmental sequelae: a case report.” BMC pregnancy and childbirth (2026). PMID: 41688955 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [119]
Ariza-Varón M, Jaramillo-Arrázola MJ, Riveros L et al.. “Meningitis caused by Fusobacterium nucleatum complicated with cavernous sinus thrombosis: A case report.” International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases (2025). PMID: 41330476 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [120]
Lin S, Scott P, Prevalska I et al.. “What's the bug?: An unusual cause of bacterial meningitis in a patient with history of transsphenoidal surgery.” The American journal of emergency medicine (2025). PMID: 39863502 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [121]
Berhe T, Melkamu Y, Amare A. “The pattern and predictors of mortality of HIV/AIDS patients with neurologic manifestation in Ethiopia: a retrospective study.” AIDS research and therapy (2012). PMID: 22490062 ↗
L3COHORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation - [122]
Bocci MG, Capecchi G, Lesci A et al.. “Transcranial Doppler Pulsatility Index and MRI Findings in Meningoencephalitis: A Pilot Observational Retrospective Cohort Study in Critically Ill Patients.” Clinics and practice (2026). PMID: 41744524 ↗
L4COHORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation - [123]
Pruitt AA. “CNS infections in patients with cancer.” Continuum (Minneapolis, Minn.) (2012). PMID: 22810134 ↗
L5CASE_REPORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation - [124]
Tian C, Liu J, Chen Z et al.. “Case report: Analysis of the efficacy and safety of anti-infectious treatment for brain abscess caused by oral anaerobes.” Frontiers in pharmacology (2025). PMID: 40417222 ↗
L4CASE_REPORTCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation - [125]
Nau R, Djukic M, Spreer A et al.. “Bacterial meningitis: an update of new treatment options.” Expert review of anti-infective therapy (2015). PMID: 26293166 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation - [126]
Cools F, Delputte P, Cos P. “The search for novel treatment strategies for Streptococcus pneumoniae infections.” FEMS microbiology reviews (2021). PMID: 33399826 ↗
L5REVIEW_NARRATIVECited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation - [127]
Pons S, Frapy E, Sereme Y et al.. “A high-throughput sequencing approach identifies immunotherapeutic targets for bacterial meningitis in neonates.” EBioMedicine (2023). PMID: 36709579 ↗
L5OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation - [128]
Cortazzo V, Romani L, Vrenna G et al.. “Expanding Diagnostic Options for Pediatric Meningitis: BCID2 Testing Results on Cerebrospinal Fluid After a Negative Meningitis/Encephalitis Panel.” Antibiotics (Basel, Switzerland) (2026). PMID: 42192741 ↗
L3OTHERCited in: Disease-Modifying & Immunotherapy Program: Sequencing, Safety Monitoring & De-escalation - [129]
Chavanet P, Fournel I, Bourredjem A et al.. “Addition of daptomycin for the treatment of pneumococcal meningitis: protocol for the AddaMAP study.” BMJ open (2023). PMID: 37491088 ↗
L5TRIAL_NONRANDOMCited in: Neurorehabilitation, Symptomatic & Supportive Care - [130]
Duval X, Taha MK, Lamaury I et al.. “One-Year Sequelae and Quality of Life in Adults with Meningococcal Meningitis: Lessons from the COMBAT Multicentre Prospective Study.” Advances in therapy (2022). PMID: 35484469 ↗
L2COHORTCited in: Neurorehabilitation, Symptomatic & Supportive Care - [131]
McGill F, Griffiths MJ, Bonnett LJ et al.. “Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study.” The Lancet. Infectious diseases (2018). PMID: 30153934 ↗
L2COHORTCited in: Neurorehabilitation, Symptomatic & Supportive Care - [132]
Fomichev D, Kalinin P, Kutin M et al.. “Extended Transsphenoidal Endoscopic Endonasal Surgery of Suprasellar Craniopharyngiomas.” World neurosurgery (2016). PMID: 27402435 ↗
L4TRIAL_NONRANDOMCited in: Neurorehabilitation, Symptomatic & Supportive Care - [133]
Mian UU, Hameed A, Azeem T et al.. “The Endoscopic Versus Open Approach for Anterior Skull Base Tumors: A Systematic Review of Comparative Outcomes and a Framework for Surgical Selection.” Neurology research international (2025). PMID: 41281588 ↗
L2SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care - [134]
Al Hamoud MA, Asiry AJ, Alahmari MS et al.. “Outcomes of Cochlear Implantation in Postmeningitis Hearing Loss: A Systematic Review and Meta-Analysis.” Ear, nose, & throat journal (2025). PMID: 40567169 ↗
L1SR_OBSCited in: Neurorehabilitation, Symptomatic & Supportive Care - [135]
van de Beek D, Farrar JJ, de Gans J et al.. “Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data.” The Lancet. Neurology (2010). PMID: 20138011 ↗
L1SR_OBSCited in: Complications, Prognosis & Natural History - [136]
Prasad M, Kumar A, Couban R et al.. “Duration of anti-seizure medicines started for acute symptomatic seizures due to acute meningitis: a systematic review and meta-analysis.” BMC medicine (2026). PMID: 42021346 ↗
L1SR_OBSCited in: Complications, Prognosis & Natural History - [137]
Jim KK, Brouwer MC, van der Ende A et al.. “Subdural empyema in bacterial meningitis.” Neurology (2012). PMID: 23136260 ↗
L4OTHERCited in: Prognosis & Natural History - [138]
van de Beek D, Brouwer MC, Thwaites GE et al.. “Advances in treatment of bacterial meningitis.” Lancet (London, England) (2012). PMID: 23141618 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History - [139]
Singh G, Prabhakar S. “The effects of antimicrobial and antiepileptic treatment on the outcome of epilepsy associated with central nervous system (CNS) infections.” Epilepsia (2008). PMID: 18754960 ↗
L5OTHERCited in: Prognosis & Natural History - [140]
Loron G, Olivier P, See H et al.. “Ciprofloxacin prevents myelination delay in neonatal rats subjected to E. coli sepsis.” Annals of neurology (2010). PMID: 21387379 ↗
L5OTHERCited in: Prognosis & Natural History - [141]
Burstein B, Waterfield T, Umana E et al.. “Prediction of Bacteremia and Bacterial Meningitis Among Febrile Infants Aged 28 Days or Younger.” JAMA (2026). PMID: 41359314 ↗
L2SR_OBSCited in: Special Populations & Pregnancy - [142]
He C, Deng Y, Li T et al.. “The Association Between Elevated Estimated Glomerular Filtration Rate and Poor Clinical Outcomes of Pediatric Patients with Community-Acquired Bacterial Meningitis Receiving Vancomycin: A Ten-Year Retrospective Cohort Study.” Infectious diseases and therapy (2025). PMID: 40679785 ↗
L3COHORTCited in: Special Populations & Pregnancy - [143]
Di Meglio L, De Luca M, Cursi L et al.. “Unraveling Pediatric Group A Streptococcus Meningitis: Lessons from Two Case Reports and a Systematic Review.” Microorganisms (2025). PMID: 40431273 ↗
L3SR_OBSCited in: Special Populations & Pregnancy - [144]
Malipiero U, Koedel U, Pfister HW et al.. “TGFbeta receptor II gene deletion in leucocytes prevents cerebral vasculitis in bacterial meningitis.” Brain : a journal of neurology (2006). PMID: 16891635 ↗
L5OTHERCited in: Prevention, Screening & Surveillance - [145]
Haine V, Oneko M, Debois M et al.. “Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study.” The Lancet. Global health (2025). PMID: 40288377 ↗
L2TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [146]
Giriappa B, Choraria N, Ponce P et al.. “Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial.” Human vaccines & immunotherapeutics (2026). PMID: 41504209 ↗
L2TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [147]
Kocaata Z, Begum S, Andani A et al.. “A systematic review of demographic and socioeconomic characteristics associated with inequalities in invasive meningococcal disease prevention in high-income countries and Latin America.” Human vaccines & immunotherapeutics (2025). PMID: 41247063 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance